Abstract MicroRNA-34 (miR-34) has been reported to be dysregulated in various human cancers and regarded as a tumor suppressive microRNA because of its synergistic effect with the well-known tumor suppressor p53. Along with the application of MRX34. the first tumor-targeted microRNA drug which based on miR-34a mimics. on phase I clinical trial (NCT01829971). https://www.roneverhart.com/Aftermath-Cabernet-Sauvignon-Napa-Valley-2017/